Effect of a microencapsulated of red pomegranate juice in diabetic cd-1 mice and fed with an atherogenic diet

Abstract

Atherosclerosis and diabetes mellitus are among the leading causes of death worldwide and in Mexico, thus presenting a problem of public health. A possible alternative for the prevention and treatment is the pomegranate, a fruit rich in polyphenolic compounds, which confer therapeutic health properties such a: antioxidant, antihypertensive, hypoglycemic, antiatherogenic and others. However, the pomegranate is not available during the year. However, microencapsulation is a method of conservation, which protects bioactive compounds present in food. The aim of the study is to evaluate the effect of subchronic administration of microencapsulated of red pomegranate juice (MRPJ) in streptozotocin-induced diabetic CD-1 mice and fed with an atherogenic diet. In vivo the Body Mass Index, damage and oxidative stress, antioxidant capacity, biochemical markers, blood pressure and histological studies of aorta, liver and kidney will be determined. MRPJ is expected to protect of the changes in the study variables. If so, the MRPJ could be used as nutraceutical product in diabetes mellitus and atherosclerosis.